Evidence map›Paper›PMID 38825331›Full record

SynthesisAmerican journal of epidemiology2024

Antidepressant drugs and risk of developing glioma: a national registry-based case-control study and a meta-analysis.

Charlotte Malmberg, Barbro Numan Hellquist, Sajna Anand Sadanandan, Maria Sandström, Wendy Yi-Ying Wu, Benny Björkblom, Beatrice Melin, Rickard L Sjöberg

Abstract readMeta-Analysis
In one paragraph

Synthesis in American journal of epidemiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Charlotte MalmbergDepartment of Clinical Sciences, Neurosciences, Umeå University, S-901 85 Umeå, Sweden.
Barbro Numan HellquistDepartment of Radiation Sciences, Oncology, Umeå University, S-901 87 Umeå, Sweden.ORCID 0000-0002-2618-7358
Sajna Anand SadanandanDepartment of Clinical Sciences, Neurosciences, Umeå University, S-901 85 Umeå, Sweden.
Maria SandströmDepartment of Radiation Sciences, Oncology, Umeå University, S-901 87 Umeå, Sweden.ORCID 0009-0002-4328-8561
Wendy Yi-Ying WuDepartment of Radiation Sciences, Oncology, Umeå University, S-901 87 Umeå, Sweden.ORCID 0000-0002-6169-5155
Benny BjörkblomDepartment of Chemistry, Umeå University, S-901 87 Umeå, Sweden.ORCID 0000-0001-9347-5790
Beatrice MelinDepartment of Radiation Sciences, Oncology, Umeå University, S-901 87 Umeå, Sweden.ORCID 0000-0002-9982-3757
Rickard L SjöbergDepartment of Clinical Sciences, Neurosciences, Umeå University, S-901 85 Umeå, Sweden.ORCID 0000-0002-8258-0699

Funding

Regional Cancer Centre of Northern SwedenSwedish Cancer FoundationUmeå University hospital
6 · The paper itself

Abstract

Whether use of antidepressants is related to the risk of developing lower-grade (WHO grades 2-3) and higher-grade (WHO grade 4) glioma was investigated in this study. A registry-based case-control study was performed with 1283 glioma case patients and 6400 age-, sex-, and geographically matched control participants who were diagnosed in Sweden during 2009-2013. Conditional logistic regression was used to analyze whether selective serotonin reuptake inhibitors (SSRIs) or non-SSRIs were associated with the risk of developing lower- or higher-grade glioma in the study population. Our results show that use of antidepressant medication was not associated with the risk of developing glioma. We also performed a meta-analysis in which the data set from the present study was combined with results from 2 previous epidemiologic studies to answer the same questions. The meta-analysis showed a modest risk reduction of developing glioma in relation to antidepressant treatment (odds ratio = 0.90; 95% CI, 0.83-0.97) when all glioma subgroups and all forms of antidepressant medications were combined. In conclusion, it remains possible that antidepressants may have common monoaminergic mechanism(s) that reduce the risk of developing glioma.

Indexed as

Antidepressive AgentsBrain NeoplasmsGliomaRegistriesSelective Serotonin Reuptake InhibitorsAdultAgedCase-Control StudiesFemaleHumansLogistic ModelsMaleMiddle AgedRisk FactorsSwedenAntidepressive AgentsSelective Serotonin Reuptake Inhibitorsantidepressantsbrain cancergliomaincidence riskselective serotonin reuptake inhibitortricyclic antidepressant

Identifiers

PMID38825331
PMCPMC11538564

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.